GlassScriptPhysician profile
Robert F Meirowitz
NPI 1639179252
$7,824.78
in general payments reported to CMS, 2019-2025
36 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $453 · 2021: $488 · 2022: $1,283 · 2023: $1,402 · 2024: $1,570 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,693 · Education: $34.80 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,693.33 |
| Education | $34.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,182.90 | 2019-2025 | |
| Janssen Biotech, INC. | $965.38 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $805.93 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $549.06 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $437.14 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $301.71 | 2020-2024 | Linzess |
| Madrigal Pharmaceuticals | $258.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $214.02 | 2021-2025 | Sutab, Suflave |
| Ardelyx, INC. | $201.12 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $199.24 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $181.56 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $181.45 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $161.72 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $157.72 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $133.96 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $118.84 | 2023 | Exalt Model D |
| Ipsen Biopharmaceuticals, INC | $109.80 | 2024-2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $101.09 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $70.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.23 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $60.32 | 2022-2023 | Rebyota |
| Ucb, INC. | $42.95 | 2019 | |
| Allergan, INC. | $39.37 | 2019 | |
| Gilead Sciences, INC. | $34.61 | 2024-2025 | |
| Amgen INC. | $32.99 | 2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.79 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $27.72 | 2020 | |
| Intercept Pharmaceuticals, INC. | $24.33 | 2019-2023 | Ocaliva |
| Ethicon US, LLC | $21.62 | 2019 | |
| Genzyme Corporation | $21.11 | 2024 | |
| Novo Nordisk INC | $19.76 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $16.41 | 2023 | Idacio |
| Organon LLC | $16.31 | 2023 | Hadlima, Renflexis |
| Celltrion USA INC. | $14.80 | 2024 | Zymfentra |
| W. L. Gore & Associates, INC. | $14.41 | 2022 | |
| Redhill Biopharma INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Meirowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.